Skip to content
TrialScanner

NCT02475213

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Phase 1CompletedMGNXLead

Registry record

Lead sponsor
MacroGenics
Conditions
Melanoma; Head and Neck Cancer; Non Small Cell Lung Cancer; Urothelial Carcinoma
Primary completion
Aug 18, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02475213 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02475213: Safety Study of Enoblituzumab... | TrialScanner